Innovent Biologics (OTCMKTS:IVBXF) Shares Up 4.2% – What’s Next?

Shares of Innovent Biologics, Inc. (OTCMKTS:IVBXF) were up 4.2% on Friday . The company traded as high as $6.15 and last traded at $6.15. Approximately 3,484 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 13,781 shares. The stock had previously closed at $5.90.

Innovent Biologics Trading Up 4.2 %

The business’s fifty day simple moving average is $5.02 and its 200-day simple moving average is $5.03.

About Innovent Biologics

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.